1. Current use of cytochrome P4 enzyme inducers such as azole group of oral antifungal medication (Ketoconazole, Itraconazole), Warfarin 2. Non exposure to Covid-19 patients 3. Those who refuse to give informed consent 4. Pregnant and lactating women will be excluded because Ivermectin is known to cross the blood placenta barrier and its effect on the unborn fetus has not been fully evaluated. Although there is no evidence of teratogenicity in the literature, the doses envisaged will be higher than that used in management of onchocerciasis. Safety first is our mantra. 5. Those with a known hypersensitivity to Ivermectin. 6. Those subjects who have had treatment with any investigational drug within 2 weeks prior to randomization. 7. Children, stigmatized population, institutionalized persons, Previously diagnosed and recovered from COVID-19. 8. Severely ill patients such as patients on ventilators, hepatic or renal impairment or unconscious. 9. Patients on known drugs that can have serious interactions with the trial drug including barbiturates (such asphennobarbital, butalbital), benzodiazepines (such as clonazepam, lorazepam), sodiumoxybate (GHB), valporic acid and herbal medicines 10. Treatment with another investigational drug.

1. Current use of cytochrome P4 enzyme inducers such as azole group of oral antifungal medication (Ketoconazole, Itraconazole), Warfarin 2. Non exposure to Covid-19 patients 3. Those who refuse to give informed consent 4. Pregnant and lactating women will be excluded because Ivermectin is known to cross the blood placenta barrier and its effect on the unborn fetus has not been fully evaluated. Although there is no evidence of teratogenicity in the literature, the doses envisaged will be higher than that used in management of onchocerciasis. Safety first is our mantra. 5. Those with a known hypersensitivity to Ivermectin. 6. Those subjects who have had treatment with any investigational drug within 2 weeks prior to randomization. 7. Children, stigmatized population, institutionalized persons, Previously diagnosed and recovered from COVID-19. 8. Severely ill patients such as patients on ventilators, hepatic or renal impairment or unconscious. 9. Patients on known drugs that can have serious interactions with the trial drug including barbiturates (such asphennobarbital, butalbital), benzodiazepines (such as clonazepam, lorazepam), sodiumoxybate (GHB), valporic acid and herbal medicines 10. Treatment with another investigational drug.